^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Title:

LENVIMA®(LENVATINIB) APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE THYMIC CARCINOMA IN JAPAN

Published date:
03/23/2021
Excerpt:
Eisai Co., Ltd….and MSD K.K….announced today that LENVIMA® (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
12/04/2020
Excerpt:
Thymomas and Thymic Carcinomas: PRICIPLES OF SYSTEMIC THERAPY...Preferred…Lenvatinib...